and Teva have announced and even made some early investments.  Bio-Similars appear to have the makings of the next “generic” type of drug, not completely generic, but a drug with the same outcome at a cheaper price.  In other news today the company announced the elimination of 900 positions, mostly sales. 
yet.  BD 
WASHINGTON -(Dow Jones)- A Johnson & Johnson (JNJ) policy director on Tuesday said the health-care conglomerate (more…)

I think we can all somewhat figure this out, but there are cases to where open heart surgery may the answer.  A short while back with my interview with Dr. Muhs, who is  the principal investigator on all of the endovascular trials conducted in the Section of Vascular Surgery at Yale University School of Medicine, I learned quite a bit. 
Each patient is different and thus each treatment plan for surgery is unique.  When devices are implanted (more…)